Revenue GrowthNear-90% revenue growth indicates strong market traction across APIs, formulations and contract research. Sustained top-line expansion supports scale economics and funds R&D and capacity investments, underpinning durable earnings potential and competitive positioning.

Gross Profit MarginPersistently strong gross margins reflect efficient manufacturing and pricing power in specialty products. Margin durability cushions operating cost increases and supports reinvestment in innovation, helping maintain operating profitability over the medium term.

Balance Sheet StrengthLow leverage and a healthy equity ratio reduce refinancing and solvency risk, giving capacity to fund R&D, capex or strategic M&A. Strong ROE signals effective capital allocation and underpins resilience through industry cycles over the coming months.

Bears Say

Net Income DeclineA decline in net income despite revenue growth points to margin pressure or rising operating costs. Continued profit erosion would limit internally generated funds for R&D and expansion, forcing tougher trade-offs between growth investments and cash preservation.

Free Cash Flow WeaknessFalling free cash flow reduces flexibility for dividends, buybacks, or discretionary R&D. If lower operating cash conversion and higher capex persist, liquidity pressure could constrain execution of strategic projects or require external financing, raising long-term risk.

EPS ContractionNegative EPS growth indicates earnings per share are declining even as revenue rises, implying margin deterioration, higher costs, or dilution. Persistent EPS contraction undermines shareholder returns and signals need for operational fixes to restore profitability trends.

Suven Pharmaceuticals Ltd. News

Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure

Suven Pharmaceuticals Ltd. ( ($IN:SUVENPHAR) ) just unveiled an update. Suven Pharmaceuticals Ltd. has received a cautionary email...

10M ago

Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay

Suven Pharmaceuticals Ltd. ( ($IN:SUVENPHAR) ) has issued an announcement. Suven Pharmaceuticals Ltd. has received a cautionary email...

10M ago

Suven Pharmaceuticals Releases Q3FY25 Conference Call Recording

Suven Pharmaceuticals Ltd. ( ($IN:SUVENPHAR) ) has provided an announcement. Suven Pharmaceuticals Ltd. has announced that the audio...

12M ago

Suven Pharmaceuticals Announces Revised Schedule for Q3 FY25 Results Conference Call

An update from Suven Pharmaceuticals Ltd. ( ($IN:SUVENPHAR) ) is now available. Suven Pharmaceuticals Ltd has announced a...

12M ago

SUVENPHAR FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹368.50 and its highest was ₹1328.20 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹145.72B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 12, 2026 which is in 11 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on Nov 12, 2025. The company reported ₹1.92 earnings per share for the quarter, beating the consensus estimate of ₹1.55 by ₹0.37.

Is Suven Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 2.69.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of ₹1.92 in its last earnings report, beating expectations of ₹1.55. Following the earnings report the stock price went down -0.253%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:SUVENPHAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.